Equities researchers at StockNews.com began coverage on shares of Syneos Health (NASDAQ:SYNH – Get Free Report) in a note issued to investors on Wednesday. The firm set a “hold” rating on the stock.
A number of other equities research analysts have also commented on SYNH. Mizuho raised their price objective on shares of Syneos Health from $38.00 to $43.00 in a report on Tuesday, May 16th. JPMorgan Chase & Co. raised shares of Syneos Health from an “underweight” rating to a “neutral” rating in a research report on Wednesday, May 10th. Barclays raised shares of Syneos Health from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, May 10th. Robert W. Baird downgraded shares of Syneos Health from an “outperform” rating to a “neutral” rating in a research report on Thursday, May 11th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Syneos Health from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Nine analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $44.00.
Syneos Health Trading Up 0.3 %
Shares of NASDAQ:SYNH opened at $42.68 on Wednesday. Syneos Health has a 12 month low of $22.89 and a 12 month high of $64.25. The company has a quick ratio of 1.20, a current ratio of 1.20 and a debt-to-equity ratio of 0.77. The company’s fifty day simple moving average is $42.35 and its 200 day simple moving average is $40.07. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 61.86 and a beta of 1.58.
Institutional Trading of Syneos Health
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Syneos Health by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,849,358 shares of the company’s stock worth $464,397,000 after buying an additional 181,422 shares during the period. Barclays PLC raised its stake in Syneos Health by 52.4% in the 2nd quarter. Barclays PLC now owns 4,664,940 shares of the company’s stock worth $196,580,000 after purchasing an additional 1,604,446 shares in the last quarter. Clearbridge Investments LLC raised its stake in Syneos Health by 3.3% in the 1st quarter. Clearbridge Investments LLC now owns 3,902,162 shares of the company’s stock worth $315,880,000 after purchasing an additional 125,011 shares in the last quarter. State Street Corp raised its stake in Syneos Health by 1.1% in the 2nd quarter. State Street Corp now owns 2,885,944 shares of the company’s stock worth $121,614,000 after purchasing an additional 31,564 shares in the last quarter. Finally, FMR LLC raised its stake in Syneos Health by 27.0% in the 1st quarter. FMR LLC now owns 2,766,984 shares of the company’s stock worth $98,560,000 after purchasing an additional 587,471 shares in the last quarter. Institutional investors own 91.16% of the company’s stock.
About Syneos Health
Syneos Health, Inc, operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.